Evaluating different physician's prescribing preference based instrumental variables in the study of beta2-agonist use and the risk of acute myocardial infarction

Md Jamal Uddin, Rolf H.H. Groenwold, Anthonius De Boer, Ana Afonso, Paola Primatesta, Claudia Becker, Svetlana V. Belitser, Arno W. Hoes, Kit C.B. Roes, Olaf H. Klungel

Research output: Contribution to journalMeeting AbstractOther research output

Abstract

Background: Instrumental variable (IV) analysis with physician's prescribing preference (PPP) as an IV has been used to control for unobserved confounding in pharmacoepidemiology. PPP can be defined in several ways, but it is unclear how different PPPs perform across databases. Objectives: To assess the validity of the IV PPP in two general practice (GP) databases in the study of inhaled long-acting beta2-agonist (LABA) use and the risk of acute myocardial infarction (AMI). Methods: Information on adult patients with a diagnosis of asthma and/or COPD and at least one prescription of an inhaled short-acting beta2-agonist (SABA)/LABA/ muscarinic antagonist (MA) was extracted from the British Clinical Practice Research Datalink (CPRD, n = 490499), and the Dutch Mondriaan (n = 27459) GP databases. Conventional Cox model and two-stage IV analysis were applied to estimate the effect of LABA vs. non-LABA (SABA/MA) on the risk of AMI. PPPs were defined by the proportion of LABA prescriptions per practice (PLP) or previous single (PPP1), or five (PPP5), or ten (PPP10) prescriptions by a physician. Quantitative methods (e.g. correlation (r), odds ratio (OR), standardized difference (SDif)) were used to assess the validity of the IVs. 95% confidence intervals (CI) for IV estimates were estimated using bootstrapping. Results: LABA was not associated with an increased risk of AMI, adjusted hazard ratio 0.96 [95%CI 0.89-1.02] (CPRD) and 1.18 [0.97-1.43] (Mondriaan) in conventional Cox model and 0.95 [0.55-1.63], 1.24 [0.40-3.60], and 1.24 [0.47-3.09] in IV analyses with PPP10 for CPRD, and PPP5 and PPP10 for Mondriaan, respectively. PLP, PPP1 and PPP5 in the CPRD and PPP1 in Mondriaan were weakly associated with LABA (r0.10) across PLP levels in Mondriaan. Conclusions: LABA use was not associated with an increased risk of AMI compared to non-LABA. Validity of IV depends on the definition of IV and the database in which it is applied. We recommend researchers to generate several possible IVs, assess their validity, and report the estimate(s) from the most valid IV.
Original languageEnglish
Article number58
Pages (from-to)32
Number of pages1
JournalPharmacoepidemiology and Drug Safety
Volume23
Issue numberS1
DOIs
Publication statusPublished - 1 Oct 2014

Keywords

  • muscarinic receptor blocking agent
  • physician
  • human
  • instrumental variable analysis
  • agonist
  • risk
  • acute heart infarction
  • pharmacoepidemiology
  • risk management
  • validity
  • data base
  • prescription
  • proportional hazards model
  • clinical practice
  • asthma
  • diagnosis
  • patient
  • general practice
  • scientist
  • hazard ratio
  • bootstrapping
  • confidence interval
  • adult

Fingerprint

Dive into the research topics of 'Evaluating different physician's prescribing preference based instrumental variables in the study of beta2-agonist use and the risk of acute myocardial infarction'. Together they form a unique fingerprint.

Cite this